Scharf Investments LLC Lowers Position in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Scharf Investments LLC trimmed its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 21.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,076,520 shares of the medical equipment provider's stock after selling 555,004 shares during the period. Smith & Nephew SNATS comprises approximately 1.8% of Scharf Investments LLC's portfolio, making the stock its 22nd largest position. Scharf Investments LLC owned about 0.47% of Smith & Nephew SNATS worth $58,911,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Sei Investments Co. boosted its position in Smith & Nephew SNATS by 229.8% during the fourth quarter. Sei Investments Co. now owns 75,215 shares of the medical equipment provider's stock valued at $1,849,000 after buying an additional 52,411 shares during the period. Townsquare Capital LLC boosted its position in Smith & Nephew SNATS by 19.0% during the fourth quarter. Townsquare Capital LLC now owns 17,557 shares of the medical equipment provider's stock valued at $432,000 after buying an additional 2,798 shares during the period. BNP Paribas Financial Markets purchased a new stake in Smith & Nephew SNATS during the fourth quarter valued at about $435,000. Barclays PLC purchased a new stake in Smith & Nephew SNATS during the fourth quarter valued at about $431,000. Finally, Principal Securities Inc. boosted its position in Smith & Nephew SNATS by 87.6% during the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after buying an additional 691 shares during the period. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Trading Up 1.2%

Shares of Smith & Nephew SNATS stock traded up $0.34 during trading on Monday, reaching $29.17. 900,876 shares of the stock were exchanged, compared to its average volume of 809,352. The company has a quick ratio of 1.33, a current ratio of 2.89 and a debt-to-equity ratio of 0.62. The stock's fifty day moving average is $28.34 and its 200 day moving average is $26.99. The firm has a market cap of $12.77 billion, a price-to-earnings ratio of 13.50, a price-to-earnings-growth ratio of 0.89 and a beta of 0.68. Smith & Nephew SNATS, Inc. has a 1 year low of $23.69 and a 1 year high of $31.72.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. UBS Group lowered shares of Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. Canaccord Genuity Group upped their price target on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a research report on Thursday, May 1st. HSBC lowered shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Hsbc Global Res lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, Wall Street Zen upgraded shares of Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 26th. Six research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.